NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 36,007 shares, a decline of 62.7% from the February 26th total of 96,641 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 28,526 shares, the days-to-cover ratio is presently 1.3 days.

NLS Pharmaceutics Price Performance

NLS Pharmaceutics stock traded down $0.25 during trading on Friday, reaching $2.22. The company had a trading volume of 17,060 shares, compared to its average volume of 18,921. The firm’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $7.08. NLS Pharmaceutics has a 1-year low of $1.89 and a 1-year high of $30.80.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.